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There is continuing debate on the optimal treatment for Grave’s thyrotoxicosis with a resultant variation in clinical practice. The
present study aimed to ascertain changes in practice in the treatment of Grave’s thyrotoxicosis in Tayside, Scotland, over the
past four decades. Methods. The “Scottish automated follow-up register” (SAFUR) was queried to identify all patients treated for
Grave’s thyrotoxicosis from 1968 to 2007 inclusive. Patients were divided into 4 groups (Groups A to D) according to the decades.
Demographic profile, treatment modalities, radioactive iodine (RAI) dose, and recurrence rates were studied and outcomes were
compared by 𝜒2 test and ANOVA using SPSS v15.0. A 𝑝 value of < 0.05 was considered significant. Results. Altogether, 3737 patients
were diagnosed with Grave’s thyrotoxicosis over the 4 decades. Use of RAI has increased from 43.1% in Group A to 68% in Group
D (𝑝 < 0.001). The dose of RAI has increased (𝑝 < 0.001) and there has been a reduction in recurrence rate with higher dose
of RAI. Surgical intervention rates decreased from 55.3% to 12.3% (𝑝 < 0.001) over time. Conclusions. Analysis of a large dataset
of patients with Grave’s thyrotoxicosis suggests increasing use of RAI as the preferred first line of treatment. Furthermore, using a
single higher dose of RAI and adoption of total thyroidectomy have decreased recurrence rates.
1. Introduction
Graves’ thyrotoxicosis, an autoimmune thyroid disorder
affecting about 0.5% of the population, is the most common
cause of diffuse toxic goiter [1]. It accounts for 60 to 80%
of patients with hyperthyroidism and shows a female pre-
ponderance with a female :male ratio of 10 : 1 [2]. The three
distinct treatment modalities (antithyroid drugs (ATDs),
radioactive iodine (131I) therapy (RAI), or surgery (total,
subtotal, or partial thyroidectomy)) commonly used in the
treatment of Graves’ thyrotoxicosis are used either singularly
or in variable combinations depending on circumstances
including disease characteristics and response to initial treat-
ment. The choice of optimal initial therapy for a patient
with newly diagnosed Graves’ thyrotoxicosis is influenced by
multiple factors and this may include patient/disease related
factors, physician related factors, and system related factors
such as cost [3, 4]. Furthermore, cultural and geographical
influences are also thought to play a role in the choice of initial
treatment offered to and accepted by patients [5].
The prevailing differences in treatment preferences for
Graves’ thyrotoxicosis have been highlighted by surveys
conducted in America, Europe, and Japan [5]. In addition,
studies have reported a similar early outcome of the disease,
irrespective of the initial treatment modality used. However,
there was a clear difference in the relapse rate with different
treatment, surgery producing the lowest relapse rates and
antithyroid drugs producing the highest [6]. The linear
association between RAI dosage and remission rates has been
investigated and recorded previously [7]. Furthermore, there
is currently no consensus on the best surgical option to treat
Grave’s thyrotoxicosis.
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Given the continuing debate on the optimal index therapy
for Graves’ thyrotoxicosis, in the current study, we investi-
gated the time trends in the choice of initial therapy used
for a large cohort of patients with newly diagnosed Graves’
thyrotoxicosis over a period of four decades. We also sought
to establish the remission rates with different treatment
modalities including variable doses of RAI and different types
of surgery that was used over the forty-year study period.
2. Methods
“Scottish automated follow-up register” (SAFUR) is a
computer-based, shared-care (between primary care and
hospital clinic) facility for automated follow-up of patients
diagnosed with thyroid disorders including hyperthyroidism
in Scotland [8]. SAFUR has been available for clinical use
since 1968 and currently has more than 20,000 patients
registered on the database. In Tayside, Scotland, over the past
two decades, a well-defined clinical pathway exists for the
care of patients with endocrine disorders including Grave’s
thyrotoxicosis. All patients with thyroid disorders referred
by the general practitioner to the hospital are first seen
by a medical endocrinologist who initiates the necessary
investigations and appropriate treatment from a hospital
based thyroid clinic. Patients are referred to an endocrine
surgeon by the medical endocrinologist for consideration
of operative treatment based on their clinical response.
Postsurgical follow-up in the initial one year after surgery is
by the surgical endocrine team and beyond one year further
long-term follow-up will be led by the medical endocrine
team. Patients are rereferred to the surgeons for any surgical
related problems. At initial diagnosis patients are registered
into the SAFUR database, a nation-wide follow-up registry
which has an automated function for periodic call back
of patients for surveillance blood checks at predetermined
times. The test results are reviewed and modifications to
treatment based on the test results are made by the hospital
based SAFUR medical endocrinology team.
From the SAFUR database, we identified all patients who
were newly diagnosed with Grave’s thyrotoxicosis in Tayside
health board region, Scotland (estimated 2010 midyear pop-
ulation of 402,641) during the period 1968–2007 inclusive.
Diagnosis of Graves’ disease was based on clinical findings
and elevated free T4 with or without an isotope scan.
Patients with toxic adenoma or toxic multinodular goiter
causing thyrotoxicosis were excluded. For each patient the
demographic data (age, gender) and clinical data including
treatment data (index treatment, second treatment, use of
RAI, dose of RAI used, use of surgery, and surgical technique
employed) were collated. Age at diagnosis was calculated
from the date of receiving first treatment. We determined
the remission and recurrence rates based on the serum
TSH levels recorded in the SAFUR database. For the study
purposes, any normal or increased TSH level after index
treatment was considered as remission. Patients who received
a second treatment and suppressed THS level after a period
of euthyroidism or hypothyroidism were considered to have
a clinically significant recurrence.
Patients were divided into four groups according to the
decade studied (Group A = 1968–1977; Group B = 1978–
1987; Group C = 1988–1997; and Group D = 1998–2007)
and outcome measures were compared between the four
groups to identify any time trends. RAI dose was grouped in
five different levels (<185MBq, 185–369MBq, 370–554MBq,
555–740MBq, and >740MBq). Age is presented as mean ±
SD. Recurrence rates are presented as percentages. The data
was analysed using SPSS software (Statistical Package for the
Social Sciences version 15.0, SPSS Inc., Chicago, IL, USA) and
comparisons weremade using 𝜒2 test and ANOVA. A 𝑝 value
of < 0.05 was considered significant.
3. Results
3.1. Baseline Characteristics. Between 1968 and 2007, 3737
patients were diagnosed with Graves’ disease in Tayside
health board region of Scotland. The number of newly reg-
istered patients with a diagnosis of Graves’ disease increased
with each decade of the study period: Group A representing
the first decade from 1968 to 1977 (𝑛 = 436); Group B from
1978 to 1987 (𝑛 = 755); GroupC from 1988 to 1997 (𝑛 = 1185);
and Group D representing the last decade from 1998 to 2007
(𝑛 = 1361) (Table 1). There was a female predominance (𝑛 =
3155, 84.4%) in thewhole study groupwith an overall female-
to-male ratio of 5.4 : 1 (Table 1).This preponderance of female
patients was stable over the forty-year study period. However,
a statistically significant increase in the proportion of male
patients diagnosed with Graves’ disease was noticed through
the four decades (12.6% versus 16.8%: Group A versus Group
D; 𝑝 = 0.035) studied (Table 1).
The mean age at diagnosis for the whole study group was
50 ± 16 years (Table 1). The overall mean age of patients with
Graves’ disease increased through the four decades and this
was statistically significant (43 ± 12 versus 53 ± 17: Group
A versus Group D; 𝑝 < 0.001) (Table 1). This increase in
mean age was true when analysed by gender, with both males
and females showing an increase through the four decades.
Figure 1 shows the age distribution for both genders and no
differences in the mean age between genders were noticed
over the four decades.
3.2. Index Therapy. The choice of index therapy used during
the four decades is shown in Table 1. Overall, antithyroid
drugs remained the least commonly used agent for initiating
treatment after diagnosis through the four decades. However,
its use as the first-line agent almost doubled in the last decade.
In the first decade nearly half of the patients (48.2%) received
surgery as the first-line treatment. However, a progressive
decline in the use of surgery is recorded through the decades
with only 11.6% patients undergoing surgery as principal
treatment for Graves’ disease in the last decade. This is in
contrast to the gradual increase in the use of RAI (36% versus
67.3%: Group A versus Group D) over the four decades. The
combined use of surgerywith postoperative RAI ablation also
saw a decline (7.1% versus 0.7%: Group A versus Group D)
through the four decades (Table 1). This shift from surgical
to medical treatment was found to be statistically significant
(𝑝 < 0.001).
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Table 1: Demographic characteristics and index therapy according to decades.
Whole study
1968–2007
Group A
1968–1977
Group B
1978–1987
Group C
1988–1997
Group D
1998–2007
Total number of GT patients (%) 3737 (100%) 436 (11.7%) 755 (20.2%) 1185 (31.7%) 1361 (36.4%)
Gender distribution
Females (%) 3155 (84.4%) 381 (87.4%) 642 (85%) 1000 (84.4%) 1132 (83.2%)
Males (%) 582 (15.6%) 55 (12.6%) 113 (15%) 185 (15.6%) 229 (16.8%)
Female :male 5.4 : 1 6.9 : 1 5.7 : 1 5.4 : 1 4.9 : 1
Overall age
Mean ± std dev 50 ± 16 43 ± 12 47 ± 15 51 ± 16 53 ± 17
Age of females
Mean ± std dev 50 ± 16 43 ± 12 47 ± 15 51 ± 16 53 ± 17
Age of males
Mean ± std dev 51 ± 16 41 ± 13 49 ± 14 50 ± 17 54 ± 16
Index treatment used
Antithyroid drugs 320 (8.6%) 27 (6.2%) 47 (6.2%) 76 (6.4%) 170 (12.5%)
Radioactive iodine 2274 (60.1%) 157 (36%) 371 (49.1%) 830 (70%) 916 (67.3%)
Surgery 873 (23.4%) 210 (48.2%) 293 (38.8%) 212 (17.9%) 158 (11.6%)
Surgery + RAI 87 (2.3%) 31 (7.1%) 28 (3.7%) 18 (1.5%) 10 (0.7%)
GT: Graves’ thyrotoxicosis; std dev: standard deviation; RAI: radioactive iodine.
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Figure 1: Age distribution of patients with Graves’ disease.
3.3. Surgery as Index Treatment. The mean age of patients
who had surgical treatment as index therapy was 37.5 ± 13.5
years. Figure 2 shows the age distribution of patients receiving
surgery. The operation of choice during the first two decades
(Groups A and B) was subtotal thyroidectomy. The surgical
practice changed in 1992 to near total or total thyroidectomy.
Consequently, Groups C and D patients had either near total
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Figure 2: Age distribution of patients who underwent surgery.
or total thyroidectomy. There was a downward trend in the
recurrence rates after surgical treatment (11.4% versus 3%:
Group A versus Group D) over the decades and this trend is
likely to reflect the change in surgical practice from subtotal
thyroidectomy to total thyroidectomy (Table 2). The mean
time from surgical treatment to recurrence was 127 ± 91
months (range: 4–338months). On the other hand, the rate of
postoperative hypothyroidism increased from 75% (Groups
A and B) to 96.4% (Groups C and D) reflecting the use of
total thyroidectomy as the preferred surgical technique.
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Table 2: Outcomes after thyroidectomy according to decade.
Total number
of patients (%)
Remission
rate (%)
Recurrence
rate (%)
Group A
(1968–1977) 241 (55%) 214 (89%) 11.4%
Group B
(1978–1987) 321 (43%) 295 (92%) 7.3%
Group C
(1988–1997) 229 (19%) 217 (95%) 3.2%
Group D
(1998–2007) 167 (12%) 167 (97%) 3%
Table 3: Outcome after different RAI dose.
RAI dose Remission
𝑛 (%)
Recurrence
𝑛 (%)
Hypothyroidism
𝑛 (%) Total
<185MBq 5 (62.5) 3 (37.5) 5 (62.5) 8
185–369MBq 244 (82.7) 51 (17.3) 265 (89.8) 295
370–554MBq 1046 (93.5) 73 (6.5) 989 (88.4) 1119
555–740MBq 74 (93.7) 5 (6.3) 70 (88.6) 79
>740MBq 708 (96.2) 28 (3.8) 617 (83.8) 736
Total 2077 (92.8) 160 (7.2) 1946 (86.9) 2237
3.4. RAI as Index Treatment. Patients who received treatment
with RAI had a mean age of 55 ± 14.5 years. Figure 3
demonstrates the age distribution of patients receiving RAI as
primary treatment.The use of RAI as index therapy increased
through the decades from 36% in the first decade (group A)
to around 70% in the last two decades (Group C and Group
D) (Table 1) of the study period. Altogether 2358 patients
had RAI but information on dose of RAI used was available
for 2237 (94.9%) patients only. There was a trend towards
usage of higher doses of RAI over the time (𝑝 < 0.001). This
was associated with a concurrent reduction in recurrence
rates following RAI ablation therapy (𝑝 < 0.001) (Figure 4).
The complete remission rate following RAI treatment was
92.8% with 7.2% patients having recurrence following RAI
treatment. This recurrence rate is comparable to the overall
recurrence rate of 6.3% following surgical treatment in the
study. Only 8.6% of patients, however, treated with ATD
showed a complete remission.
A second dose of RAI was administered to 158 patients
with a mean dose of 602.8 ± 222.5MBq. Thyroxine replace-
ment was required in 87.2% of patients (𝑛 = 2358) following
RAI therapy, a figure that was comparable to the rates of post-
operative hypothyroidism seen in patients treated surgically.
The rate of posttreatment hypothyroidism was independent
of the RAI dose at long-term follow-up (Table 3).
4. Discussion
Treatment approaches to Grave’s disease differ, but ultimately
they are dependent on age, existing comorbidities, and pref-
erence of patients and clinicians. Although most clinicians
would recommend antithyroid drugs (ATDs) as the first-line
Le
ss
 th
an
 2
0
O
ld
er
 th
an
 8
5
0.0
5.0
10.0
15.0
Pe
rc
en
t (
%
)
2
0
–2
4
2
5
–2
9
3
0
–3
4
3
5
–3
9
4
0
–4
4
4
5
–4
9
5
0
–5
4
5
5
–5
9
6
0
–6
4
6
5
–6
9
7
0
–7
4
7
5
–7
9
8
0
–8
4
Figure 3: Age distribution of patients who had RAI treatment.
Recurrence
0
5
10
15
20
25
30
35
40
Re
cu
rr
en
ce
 ra
te
 (%
)
RAI dose
>740MBq555–740370–554185–369<185MBq
Figure 4: Recurrence rate in relation to RAI dose.
therapy [1], variations in practice have been recorded between
Europe, Asia, and America [9]. Whilst, in America, ATDs
are used as an adjunct prior to index treatment with RAI or
surgery [5], in Europe andAsia ATDs are primarily employed
as the initial therapy for newly diagnosed cases with RAI
or surgery was offered as second-line treatment for those
patients who relapse on ATD. Surgical treatment may be the
preferred option for many patients as it provides immediate
symptomatic relief, does not require frequent monitoring
of thyroid function since the inevitable hypothyroidism is
treated with hormone replacement therapy, and interferes
less with patients’ complex lifestyles [4]. Furthermore, recent
Journal of Thyroid Research 5
cost-effectiveness studies have demonstrated that thyroidec-
tomymight bemore cost-effective thanRAI orATDs,without
compromising quality of life [10–12].
In view of the controversies in the management of GD,
this study, one of the largest to date, attempted to summarise,
compare, and contrast the management of patients with
Graves’ thyrotoxicosis in a health authority in Scotland over
a period of four decades.
Antithyroidmedicationwas consistently the least popular
definitive treatment modality probably due to its associated
high recurrence rate. The reported remission rate with ATDs
is around 40%–50% [9] but, in our long-term series, it was
only 8.6%. Furthermore, lifelong ATD therapy necessitates
frequent thyroid function monitoring and is associated with
life-threatening side effects such as agranulocytosis and hepa-
totoxicity [13]. Surprisingly, the use of ATDs almost doubled
in the last decade (Table 1), which is difficult to explain but
may be related to the increasing age of patients diagnosed
with Graves’ disease. Older patients may be more likely to
opt for conservative management and younger patients for
surgery since the mean age of patients who had surgery
as index therapy was 37.5 years. This is supported by other
studies who reported that patient preference was the most
common indication for thyroidectomy [4].
Another interesting trend identified regarding the choice
of therapy was the significant decline in the use of thyroidec-
tomy alone or in combination with RAI and the impressive
increase in the use of RAI. This is likely to be the result of the
increasing willingness to utilize RAI because of its safety, the
ease and convenience of administration, its lower cost, and
increasing acceptance by patients [3, 5, 9, 14]. Furthermore,
RAI has similar remission andposttreatment hypothyroidism
rates to thyroidectomy. Despite RAI becoming the first line
of definitive therapy in Graves’ disease, there is lack of
consensus regarding optimal treatment dose [1]. Treatment
with adjusted RAI dose has failed to prove superiority over
fixed standard dose regimen [15, 16]. In our study, remission
rate with a dose of 370–740MBq is higher (∼93%) than that
of other published studies [17, 18]. However, an increased
rate of remission (96.2%) has been achieved with a dose of
>740MBq (741–1110MBq) and is similar to that reported in
another study [7]. Furthermore, the rate of hypothyroidism
is fairly common in all groups and not directly related to the
RAI dose.
Despite its large sample size obtained from a national
registry our study has the following limitations. The Scot-
tish national statistics reported an increase in the midterm
population of the Tayside health board region (e.g., midterm
population; 1981 versus 2010; 397,055 versus 402,641) during
the four decades of study period. However, as the geograph-
ical region covered by the Tayside health board underwent
reorganisation during this period, wewere unable to calculate
the true changes in population-based incidence of Grave’s
disease for the region. Despite its being a prospective registry
not all data was available for the use of RAI and particularly
for the RAI dosage. The final analysis reported in the study
used the available dataset [19]. Furthermore, the scope of the
study was limited to a single health board region with all
the comparisons made being “within study” comparisons to
ascertain changeswith time through the four decades studied.
No attempt was made to compare the health board data with
the national data, as this was not available for the study group
at the time of the study.
In conclusion, the treatment of Graves’ disease in a
Scottish Health Authority has evolved over the last 40 years
favouring the early use of RAI in almost 70% of patients.
This is compatible with common practice in the United States
where the vast majority of patients are treated with RAI with
or without ATDs. A higher dose of radiation (>740MBq) is
recommended to prevent recurrence and achieve remission.
Further development of clinical pathways should be informed
by the outcomes of this longitudinal observational study.
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